Melanocortin therapies to resolve fibroblast-mediated diseases
Stromal cells have emerged as central drivers in multiple and diverse diseases, and consequently, as potential new cellular targets for the development of novel therapeutic strategies. In this review we revise the main roles of fibroblasts, not only as structural cells but also as players and regula...
Main Authors: | Natalya Khodeneva, Michelle A. Sugimoto, Camilla S. A. Davan-Wetton, Trinidad Montero-Melendez |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2023-01-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1084394/full |
Similar Items
-
Editorial: Melanocortins and melanocortin receptors in the regulation of inflammation: mechanisms and novel therapeutic strategies
by: Petteri Rinne, et al.
Published: (2023-05-01) -
Dersimelagon, a novel oral melanocortin 1 receptor agonist, demonstrates disease-modifying effects in preclinical models of systemic sclerosis
by: Masahiro Kondo, et al.
Published: (2022-09-01) -
Pro-resolving and anti-arthritic properties of the MC1 selective agonist PL8177
by: Jose Garrido-Mesa, et al.
Published: (2022-11-01) -
Regulation of Melanocortin-3 and -4 Receptors by Isoforms of Melanocortin-2 Receptor Accessory Protein 1 and 2
by: Ren-Lei Ji, et al.
Published: (2022-02-01) -
Modulation of Canine Melanocortin-3 and -4 Receptors by Melanocortin-2 Receptor Accessory Protein 1 and 2
by: Ren-Lei Ji, et al.
Published: (2022-11-01)